Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Actin vs Remedy Meds

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.0

Actin

Best for affordable compounded semaglutide with B12 enhancement
★★★3.5

Starting at $133/mo

Compounded SemaglutideB12 Enhanced
Visit Actin
7.2

Remedy Meds

Best for mainstream telehealth GLP-1 access
★★★3.6

Starting at $299/mo

CompoundedSemaglutideTirzepatide
Visit Remedy Meds

Side-by-Side Comparison

FeatureActinRemedy Meds
Overall Score7.0/107.2/10
Starting Price$133/mo$299/mo
Editorial Rating3.5 ★ /53.6 ★ /5
Features2 features3 features
States Available00
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Actin

Pros

  • Semaglutide + B12 combination for added energy support
  • Transparent pricing — exact cost shown upfront with no hidden fees
  • Competitive starting price from $133

Cons

  • Semaglutide only — no tirzepatide or liraglutide
  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed
  • Broader platform (hormones, sexual wellness, hair health)

Remedy Meds

Pros

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Cons

  • Limited public information on program details

Our Verdict

Winner: Remedy MedsScore: 7.2/10

Remedy Meds edges out Actin with a higher overall score of 7.2/10 and is particularly strong for mainstream telehealth GLP-1 access. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.